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For patients with acute COVID-19 pneumonia who require oxygen support, the International Task
Force made suggestions for remdesivir and dexamethasone, but against hydroxychloroquine.
Post-discharge management of COVID-19 survivors is a research priority. https://bit.ly/32B96uI
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ABSTRACT
Background: Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory
syndrome-coronavirus-2. Consensus suggestions can standardise care, thereby improving outcomes and
facilitating future research.
Methods: An International Task Force was composed and agreement regarding courses of action was
measured using the Convergence of Opinion on Recommendations and Evidence (CORE) process. 70%
agreement was necessary to make a consensus suggestion.
Results: The Task Force made consensus suggestions to treat patients with acute COVID-19 pneumonia
with remdesivir and dexamethasone but suggested against hydroxychloroquine except in the context of a
clinical trial; these are revisions of prior suggestions resulting from the interim publication of several
randomised trials. It also suggested that COVID-19 patients with a venous thromboembolic event be treated
with therapeutic anticoagulant therapy for 3 months. The Task Force was unable to reach sufficient
agreement to yield consensus suggestions for the post-hospital care of COVID-19 survivors. The Task Force
fell one vote shy of suggesting routine screening for depression, anxiety and post-traumatic stress disorder.
Conclusions: The Task Force addressed questions related to pharmacotherapy in patients with COVID-19
and the post-hospital care of survivors, yielding several consensus suggestions. Management options for
which there is insufficient agreement to formulate a suggestion represent research priorities.
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Non-Commercial Licence 4.0.
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Coronavirus Disease 2019 (COVID-19) is a multi-system disease caused by severe acute respiratory
syndrome-coronavirus-2 (SARS-CoV-2). More than 19 million cases of COVID-19 have been confirmed,
more than 720000 persons have died, and new cases continue to emerge at an alarming rate [1]. During
the earliest stages of the pandemic, an International Task Force was convened by the American Thoracic
Society (ATS) and European Respiratory Society (ERS) to address important clinical questions using the
scarce direct evidence that was available at the time, as well as indirect evidence. The goal of consensus
guidance is to identify opportunities to standardise care, thereby improving process-related and clinical
outcomes, and facilitating research. Management decisions for which there is insufficient agreement to
formulate consensus guidance identify topics for which there is adequate equipoise to support clinical trials.
New knowledge continues to be published, providing an increasing evidentiary basis for sound clinical
care. In this iteration of COVID-19 guidance, the Task Force updates its prior guidance on the
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pharmacological management of acute COVID-19 [2], including remdesivir, hydroxychloroquine (HCQ)
and dexamethasone. The changes to these consensus suggestions reflect the publication of several
randomised trials since the prior guidance was issued. In addition, since the number of COVID-19
survivors is increasing, little is known about the natural history of survivors [3], and no standardised
approach to caring for such individuals has been developed, the Task Force addresses questions about the
long-term follow-up of COVID-19 survivors.
The Task Force’s suggestions fall into two categories: a suggestion for the intervention (the intervention
should be used) or a suggestion against the intervention (the intervention should not be used except in the
context of a clinical trial) (table 1 and figure S1). The Task Force made seven consensus suggestions (table 2).
In the absence of sufficient agreement to make a consensus suggestion, the Task Force made no suggestion
for or against a course of action (there is clinical equipoise), thereby identifying research priorities. The Task
Force identified nine research priorities (table 3).The clinical and research suggestions in this document do
not constitute official positions of the ATS, ERS or institutions of the Task Force members. The clinical
suggestions should never be considered mandates as no suggestion can incorporate all potential clinical
circumstances. They are not intended to supplant physician judgment as it pertains to individual patients. The
suggestions are interim guidance that should be re-evaluated as new evidence accumulates.
Methods
An International Task Force was composed with the support of the ATS and ERS. Invitations were initially
sent to ATS members who are clinically active in medical centres involved in COVID-19 patient care. The
invitees were asked to suggest additional participants from around the world who were on the frontline of
COVID-19 patient care, with an emphasis on pulmonologists, critical care physicians, and infectious
disease experts. Finally, the ERS identified additional experts.
Questions of clinical importance were identified by a subcommittee that consisted of clinicians who were
establishing clinics to follow COVID-19 survivors long-term at their home institutions. The questions were
constructed using a modified PICO (Patient, Intervention, Comparator, Outcomes) format and then
modified using an iterative process of teleconferences and email dialogue. Finally, the questions were
reviewed for clarity by a separate, larger subcommittee.
Agreement was measured using the Convergence of Opinion on Recommendations and Evidence (CORE)
process, a Delphi-like process (figure 1). The CORE process is a consensus-based approach to making
clinical suggestions. It yields suggestions that are highly concordant with suggestions developed using
Institute of Medicine adherent methodology for clinical practice guidelines [4, 5]. Briefly, SurveyMonkey
software was used to create a multiple-choice survey. Each survey question consisted of three parts: 1)
presentation of the modified PICO question; 2) multiple choices including a strong or weak suggestion for
or against a course of action, or no suggestion; 3) and a free-text box for comments (figure S2). For
questions related to pharmacotherapy (i.e. remdesivir, systemic corticosteroids and HCQ) randomised
trials and large controlled observational studies were summarised in a non-systematic fashion and
provided as part of the relevant survey question. The survey was initially administered from 16–21 July
2020. A second survey was then constructed that was identical to the first, except results from the first
round were added including: 1) the proportion of participants who selected each multiple-choice option;
2) comments from the participants (table S1); and 3) references provided by the participants. The survey
was re-administered from 24–29 July 2020.
Agreement among the Task Force on directionality was tabulated for each multiple-choice question. For
example, if 5, 20, 50, 13 and 12 individuals selected a strong suggestion for, weak suggestion for, no
suggestion, weak suggestion against, and strong suggestion against, respectively, the results were reported
as 25% for the intervention, 50% neither for nor against the intervention, and 25% against the
TABLE 1 Task Force suggestions and interpretations
Task Force Interpretation
Suggests The Task Force believes that the benefits exceed the harms and the
intervention should be used
Makes no suggestion for
or against
The Task Force believes that the benefit–risk ratio is uncertain, more
evidence is needed and, for now, clinical equipoise exists
Suggests against/not The Task Force believes that the harms may exceed the benefits and,
therefore, the intervention should not be used except in the context of a
clinical trial
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intervention. At least 70% agreement was necessary to make a consensus suggestion for or against an
intervention. This threshold optimises the concordance of CORE-derived consensus suggestions with
TABLE 2 Summary of Task Force suggestions#
The Task Force made the following consensus suggestions
For hospitalised patients with COVID-19 pneumonia who require supplemental oxygen but are not
mechanically ventilated, the Task Force suggests remdesivir:
86% suggest remdesivir, 11% make no suggestion for or against remdesivir, and 3% suggest not using
remdesivir
For hospitalised patients with COVID-19 pneumonia who are mechanically ventilated, the Task Force
suggests remdesivir:
77% suggest remdesivir, 16% make no suggestion for or against remdesivir, and 7% suggest not using
remdesivir
For hospitalised patients with COVID-19 pneumonia who require supplemental oxygen but are not
mechanically ventilated, the Task Force suggests dexamethasone:
84% suggest dexamethasone, 13% make no suggestion for or against dexamethasone, and 3% suggest
not using dexamethasone
For hospitalised patients with COVID-19 pneumonia who are mechanically ventilated, the Task Force
suggests dexamethasone:
96% suggest dexamethasone, 1% make no suggestion for or against dexamethasone, and 3% suggest
not using dexamethasone
For adults who were hospitalised with COVID-19 pneumonia and had confirmed venous thromboembolism,
the Task Force suggests therapeutic anticoagulant therapy for 3 months to reduce the risk of recurrent
venous thromboembolism:
95% favour therapeutic anticoagulant therapy for 3 months, 1% favour therapeutic anticoagulant therapy
for >3 months, and 4% make no suggestion for either approach
For hospitalised patients with COVID-19 pneumonia who require supplemental oxygen but are not
mechanically ventilated, the Task Force suggests not using HCQ except within a clinical trial:
3% suggest HCQ, 9% make no suggestion for or against HCQ, and 88% suggest not using HCQ
For hospitalised patients with COVID-19 pneumonia who are mechanically ventilated, the Task Force
suggests not using HCQ except within a clinical trial:
0% suggest HCQ, 9% make no suggestion for or against HCQ, and 91% suggest not using HCQ
COVID-19: coronavirus disease 2019; HCQ: hydroxychloroquine. #: >70% agreement among Task Force
members.
TABLE 3 Summary of research priorities
The Task Force identified the following research needs for previously hospitalised patients with
COVID-19 pneumonia who were discharged in the past 30–60 days
Routine testing to establish a new baseline?
Pulmonary function testing
6-min walk test
Computed tomography of the chest
Transthoracic echocardiography
Cardiopulmonary exercise testing
Continue prophylactic anticoagulant therapy as outpatients until the D-dimer normalises?
Serological testing to assess immune response to the infection?
Attending medical visits without screening for active infection if serological tests positive?
Serological testing of household contacts to determine if mild or asymptomatic infection?
Referral to a multidisciplinary clinic for post-intensive care syndrome?






Routine referral for mental health counselling?
COVID-19: coronavirus disease 2019.
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Institute of Medicine adherent guideline suggestions [4]. Following the tabulation of results, the
manuscript was written and finalised after further iterative input from the Task Force.
Results
Invitations were sent to 112 clinicians. 99 (88%) clinicians representing 22 countries agreed to participate
in the Task Force. The lone reason for declining was being too busy with clinical care responsibilities. Two
individuals dropped out prior to this version of the guidance. Among the 97 remaining Task Force
members, 77% were male, 38% were from the USA, 33% were from Europe, 18% were from Asia, 73%
were respiratory physicians, 59% were critical care physicians, and 10% were infectious disease physicians.
71 (73%) out of the 97 remaining Task Force members completed the surveys.
Pharmacotherapy of acute COVID-19
1) For hospitalised patients with COVID-19 pneumonia who require supplemental oxygen but are not
mechanically ventilated or receiving extracorporeal membrane oxygenation (ECMO), the Task Force
suggests remdesivir: 86% suggest remdesivir, 11% make no suggestion for or against remdesivir, and
3% suggest not using remdesivir.
2) For hospitalised patients with COVID-19 pneumonia who are mechanically ventilated or receiving
ECMO, the Task Force suggests remdesivir: 77% suggest remdesivir, 16% make no suggestion for or
against remdesivir, and 7% suggest not using remdesivir.
The Task Force defined COVID-19 pneumonia as radiographic opacities or, if a chest radiograph has not
been performed, an oxygen saturation measured by pulse oximetry ⩽94% accompanied by symptoms and
signs of infection. Two randomised trials informed the Task Force.
The first was the Adaptive COVID-19 Treatment Trial (ACTT), a multi-centre, double-blind,
placebo-controlled randomised trial of 1063 COVID-19 patients that released its results early after an interim
analysis [6]. Those who received remdesivir had a shorter median (95% CI) time to recovery (11 (95% CI
9–12) days versus 15 (95% CI 13–19) days), a higher recovery rate ratio (1.32 (95% CI 1.12–1.55)), and a
PICO questions formulated
and prioritised
Webinar to discuss and clarify questions
Survey No. 1
PICO question provided
Task Force makes selections
Task Force makes comments
Survey No. 2
PICO question provided
Results from first round provided
Comments from first round provided
Task Force makes selections




No suggestion for or against
FIGURE 1 The Convergence of Opinion on Suggestions and Evidence process. PICO: Patient, Intervention,
Comparator, Outcomes.
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trend toward lower mortality (8% versus 11.6%, HR 0.70 (95% CI 0.47–1.04), p=0.059) compared to placebo.
There were potentially important subgroup differences. Among those requiring conventional supplemental
oxygen, there was improvement in recovery (rate ratio 1.47 (95% CI 1.17–1.84)) and mortality (HR 0.22
(95% CI 0.08–0.58)). However, among those requiring high-flow supplemental oxygen or noninvasive
ventilation, there were too few events to either confirm or exclude an effect on recovery (rate ratio 1.20 (95%
CI 0.79–1.81)) or mortality (HR 1.12 (95% CI 0.53–2.38)). Similarly, among those requiring invasive
mechanical ventilation or ECMO, there were too few events to either confirm or exclude an effect on
recovery (rate ratio 0.95 (95% CI 0.64–1.42)) or mortality (HR 1.06 (95% CI 0.59–1.92)).
The second was a randomised, double-blind, placebo-controlled multi-centre trial of 236 COVID-19
patients from Wuhan, China [7]. Among all patients, there was no difference in mortality (14% versus
13%), time to clinical recovery (HR 1.23 (95% CI 0.87–1.75)), or adverse effects (66% versus 64%).
However, in the subgroup of patients with <10 days of symptoms, there was a trend toward a shorter time
to clinical recovery (HR 1.52 (95% CI 0.95–2.43)). The trial was stopped early due to difficulties in
recruitment of new patients because the outbreak was controlled in Wuhan. Although remdesivir was
generally well tolerated, a higher proportion of remdesivir recipients than placebo recipients had dosing
prematurely stopped by the investigators due to adverse events (12% versus 5%) including respiratory
failure and acute respiratory distress syndrome (ARDS).
The Task Force prioritised the larger ACTT trial and concluded that the benefits of remdesivir likely
exceed its harms, burdens and cost in patients hospitalised with COVID-19 pneumonia, the population
enrolled in the trial. Task Force members who considered the trial’s subgroups in their decision making
were troubled by the lack of benefit among the subgroup of patients who received high-flow supplemental
oxygen or noninvasive ventilation, as well as the subgroup of patients who received invasive mechanical
ventilation or ECMO, and therefore chose to make no suggestion for or against remdesivir in the more
severely ill patients. This is the reason there was lower agreement in favour of remdesivir therapy among
the more severely ill patients.
3) For hospitalised patients with COVID-19 pneumonia who require supplemental oxygen but are not
mechanically ventilated or receiving ECMO, the Task Force suggests not using HCQ except within a
clinical trial: 3% suggest HCQ, 9% make no suggestion for or against HCQ, and 88% suggest not using
HCQ.
4) For hospitalised patients with COVID-19 pneumonia who are mechanically ventilated or receiving
ECMO, the Task Force suggests not using HCQ except within a clinical trial: 0% suggest HCQ, 9%
make no suggestion for or against HCQ, and 91% suggest not using HCQ.
In a prior version of the guidance, the Task Force noted that HCQ use was already widespread, so it made
a weak suggestion in favour of the use of HCQ with appropriate patient consent, data collection, data
analysis, and modification of clinical practice if indicated by the results of ongoing clinical studies [1]. The
updated suggestions were informed by the results of large observational studies and the preliminary release
of information from multiple randomised controlled trials.
Two large retrospective cohort studies from the New York City area (NY, USA), each with approximately
1500 patients, found no benefit on in-hospital mortality from HCQ [8, 9]. A large retrospective cohort
study from Detroit (MI, USA) subsequently found a mortality benefit associated with HCQ use [10],
although there is speculation that this finding may be a result of significant confounding because patients
who received HCQ were more than twice as likely to be treated with corticosteroids than those who did
not receive HCQ [11].
Multi-centre, randomised, placebo-controlled trials on HCQ are beginning to be completed. The ORCHID
(Outcomes Related to COVID-19 treated with HCQ among In-patients with symptomatic Disease) trial
was stopped early because interim data indicated that HCQ provided no additional benefit compared to
placebo control for the treatment of COVID-19 in hospitalised patients [12], and the HCQ arm of the
World Health Organization SOLIDARITY trial was stopped early due to a lack of benefit on mortality of
hospitalised patients compared to standard care [13]. According to a pre-peer-review manuscript, the
RECOVERY trial compared 1561 patients randomised to HCQ to 3155 patients randomised to standard
care [14]. HCQ did not impact mortality (rate ratio 1.09 (95% CI 0.96–1.23), p=0.18) and showed no
benefits in any other outcomes. There was no benefit in the subsets of patients requiring mechanical
ventilation (rate ratio 1.03 (95% CI 0.81−1.30)) or supplemental oxygen (rate ratio 1.08 (95% CI
0.92−1.26)) at randomisation. The HCQ arm was therefore removed from the trial. Lack of efficacy has
also been reported from a Brazilian trial of mild-to-moderate COVID-19 [15].
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In light of the new evidence, the Task Force agreed that HCQ should not be used for patients with
COVID-19 pneumonia unless in the context of clinical trials.
5) For hospitalised patients with COVID-19 pneumonia who require supplemental oxygen but are not
mechanically ventilated or receiving ECMO, the Task Force suggests dexamethasone: 84% suggest
dexamethasone, 13% make no suggestion for or against dexamethasone, and 3% suggest not using
dexamethasone.
6) For hospitalised patients with COVID-19 pneumonia who are mechanically ventilated or receiving
ECMO, the Task Force suggests dexamethasone: 96% suggest dexamethasone, 1% make no suggestion
for or against dexamethasone, and 3% suggest not using dexamethasone.
The Task Force was informed primarily by the RECOVERY trial [16]. The RECOVERY trial was a
multi-centre, open-label, randomised trial that randomly assigned hospitalised patients with COVID-19 to
dexamethasone 6 mg daily for 10 days (n=2104) or standard care (n=4321). Patients who received
dexamethasone had decreased 28-day mortality (22.9 versus 25.7%, HR 0.83 (95% CI 0.75–0.93)). Subgroup
analyses showed that the mortality benefit was greatest among patients on mechanical ventilation or ECMO
(29.3 versus 41.4%, rate ratio 0.64 (95% CI 0.51 to 0.81)), smaller among patients on supplemental oxygen
(23.3 versus 26.2%, rate ratio 0.82 (95% CI 0.72 to 0.94)), and absent among patients not on supplemental
oxygen (17.8 versus 14.0%, rate ratio 1.19 (95% CI 0.91 to 1.55)). Patients on high-flow supplemental oxygen
or noninvasive ventilation were not analysed as a separate subgroup. A subsequent observational study
reported that methylprednisolone was associated with more ventilator-free days and a higher probability of
extubation in COVID-19 patients, but it did not find a mortality difference [17].
Given the importance of the mortality outcome and the widespread availability, cost-effectiveness, and
clinical familiarity with dexamethasone, the Task Force overwhelmingly agreed that dexamethasone should
be prescribed in the populations that showed decreased mortality in the RECOVERY trial. However, the
Task Force also urged caution, particularly when administering to patients who require only a small
amount of supplemental oxygen (may not benefit as much as those who are more severely ill), are aged
>70 years and mechanically ventilated (few such patients were included in the RECOVERY trial), or are
diabetic (poor glycaemic control is associated with increased mortality in diabetics with COVID-19 [18]).
Alternative glucocorticoids are a reasonable choice (40 mg of solumedrol daily is equivalent) if
dexamethasone is not available. Use of early dexamethasone in patients with COVID-19 pneumonia to
avoid progression to ARDS and mechanical ventilation needs to be demonstrated, and delayed resolution
of viral shedding needs further study.
Follow-up of COVID-19 survivors: post-hospital testing
For adults who were hospitalised with COVID-19 pneumonia, the Task Force:
7) Makes no suggestion for or against routine post-hospital pulmonary function testing (PFT) within
30–60 days to establish a new baseline: 60% favour routine post-hospital PFT within 30–60 days, 34%
make no suggestion for or against routine PFT, and 6% favour no routine PFT.
8) Makes no suggestion for or against routine chest computed tomography (CT) within 30–60 days to
establish a new baseline: 38% favour routine chest CT within 30–60 days, 38% make no suggestion for
or against routine chest CT, and 24% favour no routine chest CT.
9) Makes no suggestion for or against routine transthoracic echocardiography (TTE) within
30–60 days to establish a new baseline: 11% favour routine TTE within 30–60 days, 66% make no
suggestion for or against routine TTE, and 24% favour no routine TTE.
10) Makes no suggestion for or against routine cardiopulmonary exercise testing (CPET) within
30–60 days to establish a new baseline: 7% favour routine CPET within 30–60 days, 66% make no
suggestion for or against routine CPET, and 27% favour no routine CPET.
Early evidence suggests that some survivors of COVID-19 develop long-term respiratory sequelae.
Abnormal lung function (i.e. reduced diffusion capacity, restrictive abnormalities, and small airways
obstruction) has been identified within 2 weeks of discharge [19] and such abnormalities appear to be
more common among patients whose acute COVID-19 was severe or who had high levels of inflammatory
markers or abnormal coagulation, as reflected by D-dimer elevation [20]. Such lung function abnormalities
are often accompanied by pulmonary fibrosis [20–23], which has been detected as early as 3 weeks after
onset of symptoms regardless of whether the acute illness was mild, moderate or severe [24, 25]. Emerging
data also suggests that cardiovascular complications (i.e. arrhythmia, acute cardiac injury and
cardiomyopathy) are common among patients with COVID-19 [26–29] and some survivors develop
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long-term cardiac sequelae; for example, structural and inflammatory changes in the heart have been
found more than 2 months after recovery [30].
There was agreement among the Task Force that it would be useful to have pulmonary (PFTs and chest
CT scans) and cardiac (TTE and CPET) measurements within 30–60 days after discharge to assess the
severity of impairment and to establish a baseline from which to follow recovery over time. However, there
was also concern about the practicality of obtaining these tests during the ongoing COVID-19 pandemic.
Many institutions are struggling to overcome backlogs that developed when elective in-person clinical
services were closed and several of the tests require extra precautions because they are aerosol generating
(i.e. PFTs and CPET), which complicates the feasibility of testing (time, cost, staff, equipment, use of
personal protective equipment) [31]. Recognition of this balance is reflected in the amount of agreement
among the Task Force, as the number who favoured testing declined as the test became more expensive or
burdensome. Ultimately, the Task Force concluded that in the absence of empirical evidence that routine
testing improves outcomes equipoise should be maintained, and no suggestions were made for or against
routine baseline testing. It is essential to note that the Task Force’s decisions were strictly for routine
baseline testing within 30–60 days. The results should not be extrapolated to testing patients with
indications for such testing, such as new symptoms, worsening symptoms or persistent symptoms. For
such patients, the need for testing should be determined on a case-by-case basis.
Follow-up of COVID-19 survivors: post-hospital anticoagulant management
11) For adults who were hospitalised with COVID-19 pneumonia, the Task Force makes no suggestion
for or against continuing prophylactic-dose anticoagulant therapy as outpatients until their
D-dimer normalises to reduce the risk of venous thromboembolism: 41% favour continuing
prophylactic anticoagulant therapy until the D-dimer normalises, 49% make no suggestion for either
approach, and 10% favour discontinuing prophylactic anticoagulant therapy on discharge.
12) For adults who were hospitalised with COVID-19 pneumonia and had confirmed venous
thromboembolism, the Task Force suggests therapeutic-dose anticoagulant therapy for 3 months to
reduce the risk of recurrent venous thromboembolism: 95% favour therapeutic anticoagulant therapy
for 3 months, 4% make no suggestion for either approach, and 1% favour therapeutic anticoagulant
therapy for >3 months.
COVID-19 patients frequently have abnormal markers of coagulation including elevated D-dimers,
increased prothrombin time, and a low platelet count [32–37]. Observational studies demonstrate that
increased D-dimer levels are associated with higher risk of intensive care unit (ICU) admission or death in
COVID-19 patients [34, 35, 38, 39] and uncontrolled studies indicate poor outcomes among patients with
severe coagulopathy [35, 38, 40]. As examples, a Chinese study of 191 patients found that an elevated
D-dimer (>1.0 µg·mL−1) on admission was associated with increased mortality (OR 18.4 (95% CI
2.6–128.5)) [38] and a case–control study of 183 COVID-19 patients demonstrated that those who died
had higher D-dimers, increased fibrin degradation products, longer prothrombin time, and longer
activated partial thromboplastin time on admission compared to survivors [39]. In addition to abnormal
markers of coagulation, post-mortem studies and lung biopsies from COVID-19 patients with ARDS
demonstrate extensive pulmonary microvascular thrombi [41–43] and observational studies report a high
prevalence of thromboembolic complications (e.g. pulmonary embolism) [32]. Thrombotic findings are the
basis for anticoagulant therapy in COVID-19.
Prophylactic dose anticoagulant therapy
In hospitalised patients without COVID-19, extending thromboprophylaxis post-discharge reduces
outpatient venous thromboembolism at a cost of more frequent severe bleeding [44, 45]. However, it is
uncertain if these effects can be extrapolated to patients with COVID-19. In an uncontrolled study of 184
COVID-19 patients, all of whom received pharmacological thromboprophylaxis, the cumulative incidence
of a composite outcome (symptomatic pulmonary embolism, deep-vein thrombosis, ischaemic stroke,
myocardial infarction or systemic arterial embolism) was nearly 50%, with the majority (87%) of events
being pulmonary embolism [46]. In a retrospective cohort study of 449 patients with severe COVID-19,
there was no difference in 28-day mortality when heparin- and non-heparin-treated patients were
compared [34]. Mortality was lower among heparin users in the subgroups of patients with a
sepsis-induced coagulopathy score over four and patients with a D-dimer level more than six-times the
upper limit of normal. Thus, to date, there is no definitive evidence that prophylactic-dose anticoagulant
therapy benefits patients with COVID-19. A substantial number of clinical trials are in progress
(ClinicalTrials.gov) and should provide definitive answers in the coming months.
Given the paucity of evidence in COVID-19 patients, nearly half of the Task Force was unwilling to make
a recommendation for or against extended prophylactic-dose anticoagulation in patients with COVID-19,
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highlighting the uncertainty about this issue and the need for empirical research. It is noteworthy that a
sizeable minority (41%) of the Task Force was willing to use prophylactic-dose anticoagulation
post-discharge until D-dimers normalised, indicating concern about the effectiveness of routine
thromboprophylaxis and the importance of COVID-19-related thrombosis on long-term outcomes.
Therapeutic dose anticoagulant therapy
There is no empirical evidence regarding the optimal duration of treatment of venous thromboembolism
in patients with COVID-19. Therefore, the Task Force’s decision was informed by indirect evidence from
patients without COVID-19, as summarised in clinical practice guidelines [47]. The Task Force concluded
that COVID-19 should be considered a provoking factor and, therefore, COVID-19 patients with
confirmed venous thromboembolism should be treated with therapeutic-dose anticoagulation for
3 months.
Follow-up of COVID-19 survivors: post-hospital infection control
13) For adults who were hospitalised with COVID-19 pneumonia, the Task Force makes no suggestion
for or against routine post-hospital serological testing to assess their immune response to the
infection: 31% favour routine serological testing, 57% make no suggestion for or against either approach,
and 12% favour no routine serological testing.
14) For adults who were hospitalised with COVID-19 pneumonia, the Task Force makes no suggestion
for or against allowing patients whose serological tests demonstrate antibodies against SARS-CoV-2 to
attend in-person medical appointments without screening for active infection: 23% favour allowing the
patient to attend without screening, 39% make no suggestion for or against either approach, and 38%
favour requiring the usual screening for active infection.
15) For the household contacts of adults who were hospitalised with COVID-19 pneumonia, the Task
Force makes no suggestion for or against routine serological testing to determine if they had mild or
asymptomatic infection: 33% favour routine serological testing, 49% make no suggestion for or against
routine serological testing, and 18% favour no routine serological testing.
The antibody response to SARS-CoV-2 in hospitalised patients with PCR-confirmed COVID-19 has not
been fully characterised. Patients can develop antibodies to any of the following four major structural viral
proteins: spike (S), nucleocapsid (N), matrix (M), and envelope (E). Antibodies to the S protein are
considered neutralising antibodies since they can block the fusion of SARS-CoV-2 to the ACE-2 receptor
on epithelial cells.
Data from a limited number of cohort studies of hospitalised patients with COVID-19 suggest that almost
100% of hospitalised patients will develop immunoglobulin (Ig)M and IgG antibodies by the tenth day of
hospitalisation [48–53]. Several correlations have been observed: more severe disease is associated with
higher antibody levels; more severe disease is associated with higher titres of neutralising antibodies and
higher total antibody levels are associated with higher levels of neutralising antibodies. IgM seroconversion
occurs earlier than IgG in most patients but, occasionally, it may occur at the same time or after IgG.
Further studies are necessary to define the duration of antibody responses, presence and duration of
neutralising antibodies, tissue distribution of antibodies, and possible cross-reactivity with any of the four
endemic human coronaviruses. Due to the current knowledge gaps, the Task Force concluded that current
data on antibody testing is insufficient to guide clinical decision making, although the Task Force
recognised that antibody testing may help in public health surveillance to define disease burden and in the
identification of convalescent plasma donors.
Follow-up of COVID-19 survivors: post-hospital physical and mental rehabilitation
For adults who were hospitalised with COVID-19 pneumonia, the Task Force:
16) Makes no suggestion for or against routine referral to a dedicated multidisciplinary clinic
specialising in post-intensive care syndrome (PICS): 44% favour routine referral, 49% make no
suggestion for or against either approach, and 7% favour follow-up with primary care with as-needed
specialty referral.
17) Makes no suggestion for or against routine referral to a dedicated pulmonary rehabilitation
programme regardless of the presence or severity of lung function abnormalities: 17% favour routine
referral regardless of lung function, 49% make no suggestion for or against either approach, and 34%
favour referral based on lung function abnormalities.
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18) Makes no suggestion for or against routine post-hospital screening for cognitive impairment
within 30–60 days: 29% favour routine screening, 55% make no suggestion for or against routine
screening, and 16% favour no routine screening.
19) Makes no suggestion for or against routine post-hospital screening for depression, anxiety, and
post-traumatic stress disorder (PTSD) within 30–60 days: 69% favour routine screening, 24% make no
suggestion for or against routine screening, and 7% favour no routine screening.
20) Makes no suggestion for or against routine post-hospital referral for mental health counselling
within 30–60 days: 9% favour routine referral, 71% make no suggestion for or against routine referral, and
20% favour no routine referral.
Most evidence related to the recovery of hospitalised patients is derived from cohorts of ICU survivors.
Physical, cognitive and mental health abnormalities are common among survivors and such deficits are
collectively termed PICS [54–58]. Roughly 80% of COVID-19 survivors experience physical, cognitive or
mental health impairments consistent with PICS after discharge [59–61]. PICS clinics have become part of
post-ICU care in some parts of the world [62–64] but there is little empirical evidence about the outcomes
of such clinics. Half of the Task Force declined to suggest for or against routine referral to a PICS clinic
because, in the absence of empirical evidence of a benefit, they did not want to reduce equipoise that may
be necessary across settings with variable resources. It is noteworthy, however, than among Task Force
members who indicated a preference, routine referral to a PICS clinic was chosen six-times more often
than follow-up with a primary care clinician with as-needed consultation of specialists.
Physical outcomes
Half of COVID-19 survivors report fatigue and >40% have persistent dyspnoea at 3 months [65].
Pulmonary rehabilitation provides exercise training and education to improve the physical and
psychological condition of individuals with chronic respiratory diseases [66, 67]. While the strongest data
exist for patients with COPD [68], pulmonary rehabilitation is also beneficial in other chronic respiratory
conditions [69], including survivors of critical illness due to viral pneumonias [70–72]. Early experience
with pulmonary rehabilitation in COVID-19 survivors from China indicates that a 6-week pulmonary
rehabilitation programme can improve pulmonary function, quality of life measures and anxiety [73],
although additional research is needed [73–76].
Half of the Task Force declined to suggest for or against referral of all COVID-19 survivors to pulmonary
rehabilitation because, in the absence of empirical evidence of a benefit, they did not want to reduce the
equipoise that may be necessary across settings with variable resources. Among the remaining half of the
Task Force who suggested pulmonary rehabilitation, two-thirds thought that referral should be based upon
lung function abnormalities and one-third thought that referral should occur regardless of the presence or
severity of lung function abnormalities.
Cognitive outcomes
No studies have reported the prevalence of cognitive impairment among survivors of COVID-19, so
extrapolation from other severe illnesses is necessary. Cognitive impairment comparable to mild
Alzheimer’s dementia has been estimated to occur in 25% of survivors of critical illness [77] and may be
associated with prolonged delirium [78, 79], severe hypoxaemia [78–81], early neurological manifestations
[82], and duration of sedative-analgesia administration [80, 83]. COVID-19 patients have risk factors for
cognitive deficits [84], but there is no empirical evidence that cognitive deficits are as frequent among
COVID-19 survivors or that interventions can improve cognitive outcomes [85, 86]. Therefore, the Task
Force was unwilling to suggest for or against routine screening for cognitive deficits 30–60 days after
discharge.
Mental health outcomes
Mental health experts have warned that PTSD could become the “second tsunami of the SARS-CoV-2
pandemic” [87] affecting the survivors of acute illness and their families, as well as the population at large
living under prolonged conditions of heightened anxiety and isolation [88]. There is little data on the
epidemiology of mood disorders in COVID-19 patients, but small single-centre studies report symptoms
of depression and anxiety in over one-third of COVID-19 patients [89], consistent with findings in
survivors of other serious illnesses [89, 90].
Despite limited empirical evidence, the Task Force fell just one vote shy of making a consensus suggestion
for routine screening for depression, anxiety and PTSD, reflecting the long-established acceptability of
screening for mental health conditions as established by the US Preventative Services Task Force [91]. Any
mental health screening programme is most beneficial when directly linked to systems for follow-up and
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treatment of patients who screen positive [91]. The Task Force did not agree with routine referral for mental
health counselling, reflecting the Task Force’s preference to focus mental health counselling resources on
those who screen positive, unless empirical evidence of a benefit from routine referral is established.
Conclusions
The International Task Force used a Delphi-like process called the CORE process to address clinical
questions related to pharmacotherapy of acute COVID-19 pneumonia and the outpatient follow-up of
COVID-19 survivors. The former was informed by accumulating empirical evidence, whereas the latter
was informed by clinical rationale because no empirical evidence exists. There are two main goals of
consensus suggestions. The first is to standardise care, thereby improving outcomes by eliminating
dangerous outlying practices and facilitating research by defining usual care (table 2). The second is to
identify key areas where equipoise (uncertainty) exists and research is needed (table 3).
A suggestion for an intervention conveys the Task Force’s belief that the benefits exceed the harms and,
therefore, the intervention should be used. The Task Force made consensus suggestions for remdesivir and
dexamethasone in patients with acute COVID-19 pneumonia who require any type of oxygen support: i.e.
conventional supplemental oxygen, high flow supplemental oxygen, noninvasive ventilation, invasive
mechanical ventilation, or ECMO. It is noteworthy that there was more agreement for remdesivir in less
severely ill patients (i.e. conventional supplemental oxygen) than more severely ill patients (i.e. invasive
mechanical ventilation or ECMO) and, conversely, there was more agreement for dexamethasone in more
severely ill patients than less severely ill patients, reflecting the trends in beneficial outcomes across
subgroups in the clinical trials and some Task Force members’ willingness to incorporate the subgroup
analyses into their clinical decisions. The Task Force also suggested therapeutic anticoagulant therapy for
3 months in COVID-19 patients with venous thromboembolism, rather than a longer duration.
In contrast, a suggestion against an intervention indicates that the intervention should not be used unless
in the context of a clinical trial. The Task Force suggested against HCQ on the basis of accumulating
empirical evidence that HCQ confers no benefit in the populations considered by the Task Force. For all
other questions there was insufficient agreement to make a consensus suggestion, reflecting scarcity of
empirical evidence and the Task Force’s view that in the absence of empirical evidence of benefit,
equipoise should be maintained.
The primary strength of the guidance is the derivation of suggestions using a process that has been shown to
create suggestions that are usually concordant with guideline suggestions created using Institute of Medicine
adherent methodology [4, 5]. In addition, the large, multi-disciplinary International Task Force was
composed of clinicians from countries with a high prevalence of COVID-19, providing a volume of
non-systematic clinical observations greater than most uncontrolled studies. This is particularly important
because, in the absence of empirical evidence, judgments must be informed by non-systematic observations.
Finally, the time from finalising the questions to completing the suggestions was <14 days; therefore, the
suggestions are relatively up to date despite the rapid emergence of new evidence during the pandemic.
The primary weakness of the guidance is that evidence is being generated and published so quickly that
guidance can become outdated in the short duration between completion and publication. Another
limitation is the lack of a formal evidence synthesis to inform the Task Force’s suggestions, although it is
unlikely that the Task Force was unaware of major relevant randomised trials or large controlled
observational studies because the body of evidence is still quite small given the short duration since the
onset of the COVID-19 pandemic. Finally, the CORE process is a relatively new process that has been
validated by a single group of investigators using ATS clinical practice guidelines; thus, its generalisability
to other groups and non-respiratory topics is uncertain.
It is noteworthy that the International Task Force made no suggestion for or against routine referral for
pulmonary rehabilitation, pulmonary function testing, or mental health testing within 30–60 days after
discharge despite an ERS/ATS Task Force on pulmonary rehabilitation making suggestions in favour of
these actions within 6–8 weeks in a recently published report that used similar methods [92]. In studies
that validated the CORE process, the rare discordant recommendations were typically attributable to
different panels with varying interpretations of scarce or low quality evidence [4, 5]. This is probably the
reason for the different suggestions from our International Task Force and the ERS/ATS Task Force on
pulmonary rehabilitation. Specifically, the ERS/ATS Task Force on pulmonary rehabilitation was composed
of pulmonary rehabilitation experts who were probably more confident that these actions confer beneficial
effects and, therefore, more willing to suggest the actions despite minimal evidence. In contrast, our
International Task Force was more circumspect, conveying a preference to make no recommendation for
or against the actions and to maintain equipoise until empirical evidence is published given the resources
necessary to implement the suggestions. Importantly, the two groups do not recommend opposite or
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different courses of action; rather, one group was willing to suggest a course of action now, whereas the
other group decided to withhold its endorsement pending more evidence. These differences highlight the
need to reconsider all suggestions as new evidence accumulates.
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